论文部分内容阅读
目的分析研讨中药联合硼替佐米为主方案治疗初发或复发难治性多发性骨髓瘤疾病的临床疗效和不良反应状况。方法共86例研讨对象,均属于2015年3月至2016年5月期间收治的初发或复发难治性多发性骨髓瘤患者,按治疗方式分43例对照组(硼替佐米治疗)和43例研究组(中药+硼替佐米治疗),观察治疗状况,并对比分析。结果研究组治疗总疗效(88.37%)比对照组总疗效(76.74%)高,组间数据有统计学意义(P<0.05)。研究组不良反应(9.30%)虽低于对照组(11.63%),但组间数据无统计学意义(P>0.05)。结论研究组总不良反应较中药联合硼替佐米药物在初发或复发难治性多发性骨髓瘤疾病治疗上应用价值较大,疗效突出,不良反应低,进而达到治疗的目的,改善其生活质量。
Objective To analyze the clinical efficacy and side effects of traditional Chinese medicine combined with bortezomib in the treatment of primary or recurrent refractory multiple myeloma. Methods A total of 86 subjects were included in the study. Among the 86 patients with newly diagnosed or relapsed refractory multiple myeloma who were treated between March 2015 and May 2016, 43 patients (bortezomib) and 43 Cases of research group (Chinese medicine + bortezomib treatment), observe the treatment, and comparative analysis. Results The total effective rate of the study group (88.37%) was higher than that of the control group (76.74%), with statistical significance (P <0.05). Adverse reactions in the study group (9.30%) were lower than those in the control group (11.63%), but there was no significant difference between the two groups (P> 0.05). Conclusions The total adverse reactions of the study group are more valuable than traditional Chinese medicine combined with bortezomib in the treatment of primary or recurrent refractory multiple myeloma diseases, with outstanding curative effect and low adverse reactions, so as to achieve the purpose of treatment and improve the quality of life .